Victory Capital Management Inc. Purchases 43,282 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Victory Capital Management Inc. lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 139,891 shares of the biopharmaceutical company’s stock after purchasing an additional 43,282 shares during the quarter. Victory Capital Management Inc. owned about 0.13% of Regeneron Pharmaceuticals worth $99,649,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Crestwood Advisors Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 18.4% in the third quarter. Crestwood Advisors Group LLC now owns 476 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 74 shares during the last quarter. Catalina Capital Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 13.6% in the third quarter. Catalina Capital Group LLC now owns 343 shares of the biopharmaceutical company’s stock worth $361,000 after purchasing an additional 41 shares during the last quarter. Concurrent Investment Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.6% in the third quarter. Concurrent Investment Advisors LLC now owns 861 shares of the biopharmaceutical company’s stock worth $906,000 after purchasing an additional 30 shares during the last quarter. Graypoint LLC raised its stake in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Graypoint LLC now owns 2,346 shares of the biopharmaceutical company’s stock worth $2,466,000 after purchasing an additional 76 shares during the last quarter. Finally, Montecito Bank & Trust raised its stake in shares of Regeneron Pharmaceuticals by 89.5% in the third quarter. Montecito Bank & Trust now owns 1,114 shares of the biopharmaceutical company’s stock worth $1,171,000 after purchasing an additional 526 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. TD Cowen decreased their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Piper Sandler decreased their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $698.44 on Friday. The stock has a market cap of $76.36 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a 50-day simple moving average of $696.22 and a two-hundred day simple moving average of $856.82. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.86 earnings per share. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.